Lacticaseibacillus paracasei LP-18 Alleviates Post-Semaglutide Weight Rebound and Metabolic Dysfunction in Obese Mice
- 1Moon (Guangzhou) Biotech Co., Ltd., Huangpu District, Guangzhou 510530, China
- 2Department of Ocean Science and Engineering, Southern University of Science and Technology (SUSTech), Shenzhen 518055, China
Abstract
Background: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates significant anti-obesity and hypoglycemic effects in high-fat-diet (HFD)-induced obese models. However, both clinical and preclinical evidence indicates that semaglutide discontinuation inevitably leads to body weight rebound and progressive metabolic deterioration, severely compromising long-term therapeutic efficacy. Methods: To assess whether Lacticaseibacillus paracasei LP-18 alleviates post-semaglutide metabolic deterioration, we first confirmed its anti-obesity effect in HFD-fed mice, then used a three-stage model: HFD-induced obesity (4 weeks), semaglutide treatment (4 weeks), and withdrawal with or without L. paracasei LP-18 (4 weeks). Results:L. paracasei LP-18 supplementation effectively prevented post-discontinuation weight rebound and reduced cumulative energy intake while maintaining glucose homeostasis through decreased fasting and postprandial blood glucose levels. L. paracasei LP-18 also ameliorated dyslipidemia, reduced liver weight and hepatic lipid deposition, and attenuated white adipose tissue expansion and adipocyte hypertrophy. Mechanistically, L. paracasei LP-18 enriched beneficial taxa (Lacticaseibacillus, Bifidobacterium, Faecalibaculum) and depleted obesity-associated genera (Oribacterium, Anaerotruncus, Dorea), while restoring colonic barrier integrity via increased mucus layer thickness, goblet cell density, and upregulation of Muc2, ZO-1, and Occludin. Conclusions: These findings suggest that L. paracasei LP-18 is a promising probiotic strategy to alleviate post-semaglutide weight rebound and metabolic dysfunction, and its beneficial effects are associated with modulation of gut microbiota and preservation of intestinal barrier integrity.
Related
- Lacticaseibacillus paracasei INIA P708: a safe human isolate with probiotic and technological potential.
- Akkermansia muciniphila improves synaptic remodeling and alleviates sepsis-associated cognitive dysfunction via regulating the gut-brain axis
- Ginsenoside Rg1 Alleviates Chronic Obstructive Pulmonary Disease Partially Through Regulating ABCB1-Mediated Mitochondrial Dysfunction.
- Pediococcus acidilactici Long21 Alleviates Intestinal Sensitivity and Improves Gut Health in German Shepherd Dogs by Regulating Intestinal Metabolic Profiles
- Beyond Vitamin D Deficiency: Maternal Diet, Metabolic Dysfunction, and Vitamin D Signaling in Developmental Programming
BibTeX
@article{cai2026lacticaseibacillus,
title = {{Lacticaseibacillus paracasei LP-18 Alleviates Post-Semaglutide Weight Rebound and Metabolic Dysfunction in Obese Mice}},
author = {Wenjiao Cai and Ping Kong and Baojia Huang and Wenbin Xue and Chenchen Zhang and Zhou Lan and Amanda Juan Chen and Yibo Xian},
journal = {Metabolites},
year = {2026},
month = oct,
doi = {10.3390/metabo16110832},
url = {https://www.mdpi.com/2218-1989/16/11/832},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Lacticaseibacillus paracasei LP-18 Alleviates Post-Semaglutide Weight Rebound and Metabolic Dysfunction in Obese Mice
AU - Wenjiao Cai
AU - Ping Kong
AU - Baojia Huang
AU - Wenbin Xue
AU - Chenchen Zhang
AU - Zhou Lan
AU - Amanda Juan Chen
AU - Yibo Xian
PY - 2026
DA - 2026/10/30
JO - Metabolites
DO - 10.3390/metabo16110832
UR - https://www.mdpi.com/2218-1989/16/11/832
AB - Background: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates significant anti-obesity and hypoglycemic effects in high-fat-diet (HFD)-induced obese models. However, both clinical and preclinical evidence indicates that semaglutide discontinuation inevitably leads to body weight rebound and progressive metabolic deterioration, severely compromising long-term therapeutic efficacy. Methods: To assess whether Lacticaseibacillus paracasei LP-18 alleviates post-semaglutide metabolic deterioration, we first confirmed its anti-obesity effect in HFD-fed mice, then used a three-stage model: HFD-induced obesity (4 weeks), semaglutide treatment (4 weeks), and withdrawal with or without L. paracasei LP-18 (4 weeks). Results:L. paracasei LP-18 supplementation effectively prevented post-discontinuation weight rebound and reduced cumulative energy intake while maintaining glucose homeostasis through decreased fasting and postprandial blood glucose levels. L. paracasei LP-18 also ameliorated dyslipidemia, reduced liver weight and hepatic lipid deposition, and attenuated white adipose tissue expansion and adipocyte hypertrophy. Mechanistically, L. paracasei LP-18 enriched beneficial taxa (Lacticaseibacillus, Bifidobacterium, Faecalibaculum) and depleted obesity-associated genera (Oribacterium, Anaerotruncus, Dorea), while restoring colonic barrier integrity via increased mucus layer thickness, goblet cell density, and upregulation of Muc2, ZO-1, and Occludin. Conclusions: These findings suggest that L. paracasei LP-18 is a promising probiotic strategy to alleviate post-semaglutide weight rebound and metabolic dysfunction, and its beneficial effects are associated with modulation of gut microbiota and preservation of intestinal barrier integrity.
SN - 2218-1989
ER -